Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 2Pancreatic Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

Gemcitabine 57130-nm albumin-bound paclitaxel 35Specimen Handling 26Magnetic Resonance Spectroscopy 21Albumin-Bound Paclitaxel 21Fluorouracil 20Leucovorin 19Irinotecan 19Oxaliplatin 17Biopsy 17Taxes 16pembrolizumab 13Cyclophosphamide 11Cisplatin 11fludarabine 10Cetuximab 9Capecitabine 8Nivolumab 7Carboplatin 7irinotecan sucrosofate 6durvalumab 6dehydroftorafur 6Radiosurgery 6Pemetrexed 6olaparib 5Ipilimumab 5Erlotinib Hydrochloride 5trastuzumab deruxtecan 4aldesleukin 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × lanreotide × 90 days × Clear all
NCT06807437 2026-03-31

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

SWOG Cancer Research Network

Phase 3 Recruiting
274 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡